Management of Sunshine Biopharma Alarmed by the Recent World Health Organization Report That Cancer Is on the Rise
March 31 2014 - 8:00AM
Marketwired
Management of Sunshine Biopharma Alarmed by the Recent World Health
Organization Report That Cancer Is on the Rise
MONTREAL, QC--(Marketwired - Mar 31, 2014) - Sunshine Biopharma
Inc. (OTCQB: SBFM), a pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of various forms of cancer, has issued a response to the
recently released reports by the World Health Organization and the
Pancreatic Cancer Action Network.
According to "World Cancer Report 2014" issued in February by
the World Health Organization, cancer is on the rise and has become
a leading cause of death worldwide, accounting for 8.2 million
deaths in 2012. Lung cancer accounted for 1.59 million deaths
and breast cancer represented half a million deaths. The
report also says that cancer cases are expected to rise
significantly: "It is expected that annual cancer cases will rise
from 14 million in 2012 to 22 million within the next two
decades."
Additionally the Pancreatic Cancer Action Network released a
special report entitled "The Alarming Rise of Pancreatic Cancer
Deaths in the United States: Why We Need to Stem the Tide
Today." The report noted that "(t)he alarming findings
presented in the report include the fact that by the year 2020, and
possibly as early as 2015, pancreatic cancer will move from the
fourth leading cause of cancer death to the second leading cause of
cancer death in the United States."
"We are alarmed and impassioned by these trends to move
vigorously ahead with our clinical development of Adva-27a for
aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief
Executive Officer of Sunshine Biopharma. "The Company is
planning a Phase I clinical trial of Adva-27a for pancreatic cancer
in parallel to the Phase I clinical trial of Adva-27a for multidrug
resistant breast cancer to be conducted at McGill University's
Jewish General Hospital in Montreal (Canada)."
Sunshine Biopharma recently reported that it has initiated the
construction of mouse xenograft models for pancreatic cancer as
part of the plans of positioning Adva-27a for clinical development
for pancreatic cancer in parallel with multidrug resistant breast
cancer. Adva-27a is Sunshine Biopharma's lead anticancer
compound, a small molecule that has recently been shown to be
effective at killing multidrug resistant breast cancer cells,
small-cell lung cancer cells, uterine sarcoma cells and pancreatic
cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Adva-27a is currently in the
IND-Enabling stage of development. The original U.S. patent
covering Adva-27a was issued on August 7, 2012 under U.S. patent
number 8,236,935.
Safe Harbor Forward-Looking Statements To the extent that
statements in this press release are not strictly historical,
including statements as to revenue projections, business strategy,
outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the
success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The forward-looking statements contained in this
release are subject to certain risks and uncertainties that could
cause actual results to differ materially from the statements
made.
For Additional Information Contact: Camille Sebaaly CFO Sunshine
Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com